CCO Treatment Updates
Novel Mechanisms of Action in Adjuvant Therapy: Bisphosphonates and Targeted Agents in Solid Tumors
Expanding the Targets in Adjuvant Therapy |
Module 1 of 5 |
|
|
|
Adam M. Brufsky, MD, PhD, provides an overview of targeted therapies in multiple tumor types.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Define the rationale for and the mechanism of action of targeted therapies in multiple tumor types
- Cite recent clinical trial data on agents targeting the HER family of receptor tyrosine kinases for the treatment of solid tumors
- Discuss results from clinical trials investigating the safety and efficacy of antiangiogenesis agents for the treatment of multiple tumor types
- Describe the role that bisphosphonates play in managing bone health in cancer patients
Abstract
|
Bisphosphonates: Rationale for Use as Adjuvant Therapy |
Module 2 of 5 |
|
|
|
Adam M. Brufsky, MD, PhD, provides an overview of the potential mechanisms by which bisphosphonates may block metastasis, prevent bone destruction, inhibit tumor growth, and stimulate host immune mechanisms.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the mechanisms by which bisphosphonates inhibit the maturation of osteoclasts
- Recount data from preclinical studies supporting the role of bisphosphonates in preventing tumor cell proliferation, invasion, and adhesion
- Summarize data from clinical trials investigating the use of bisphosphonates in the adjuvant setting
Abstract
|
Clinical Data on the Use of Bisphosphonates in the Adjuvant Treatment of Breast Cancer |
Module 3 of 5 |
|
|
|
Michael Gnant, MD, reviews the mechanisms of action of bisphosphonates and summarizes the results of several recent breast cancer clinical trials investigating the effect of bisphosphonate therapy on bone health, metastasis, tumor burden, and survival.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the impact of malignancy and cancer therapy on bone health
- Discuss preclinical data on the potential mechanisms by which bisphosphonates exert antitumor activity
- Summarize efficacy and safety data from recent clinical trials investigating the use of bisphosphonates in the adjuvant treatment of breast cancer
- Articulate the results of studies investigating the effect of bisphosphonate therapy on persistent disseminated tumor cells
Abstract
|
Beyond Breast Cancer: An Update on Bisphosphonates for Prostate Cancer |
Module 4 of 5 |
- Matthew R. Smith, MD, PhD
|
|
|
Matthew R. Smith, MD, PhD, reviews clinical data regarding the adjuvant use of bisphosphonates in the treatment of patients with prostate cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize clinical trial results of adjuvant bisphosphonate treatment for patients with prostate cancer
- Discuss the use of zoledronic acid for the treatment of prostate cancer patients
- Explain why targeting RANKL is a potentially beneficial strategy for the treatment of patients with prostate cancer
- Describe prevention strategies for treatment-related osteoporosis in men
Abstract
|
Interactive Dialogue Session: Clinical Considerations and Debates in Adjuvant Therapy |
Module 5 of 5 |
 
- Adam M. Brufsky, MD, PhD
- Michael Gnant, MD
- Matthew R. Smith, MD, PhD
|
|
|
Adam M. Brufsky, MD, PhD; Michael Gnant, MD; and Matthew R. Smith, MD, PhD, present cases and clinical questions regarding the use of bisphosphonates and targeted therapies for treating breast and prostate cancer patients in the adjuvant setting.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Compare different bisphosphonates used for the adjuvant treatment of breast and prostate cancer
- Discuss evidence-based data regarding the adjuvant use of bisphosphonates in patients with breast cancer
- Describe fracture risk assessment in the setting of cancer
Abstract
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME/CE-certified components of this program.
|